Korean J Hepatol.
1999 Jun;5(2):97-104.
The Effect of Long-erm Lamivudine Therapy for Chronic Liver Disease due to Hepatitis B Virus
Abstract
- BACKGROUND/AIMS
We studied to evaluate the virological and biochemical responses to lamivudine and to detect YMDD mutants in patients who received long-erm lamivudine therapy.
METHODS
We conducted a one-ear trial of lamivudine in 45 Korean patients with chronic liver disease due to hepatitis B virus. The patients were treated with a single oral average dose of 100 mg of lamivudine every day for 12 months.
RESULTS
The suppression of serum HBV DNA was sustained in 77.8% of the patients and the normalization of serum ALT in 80%. The proportions of patients with HBeAg seroconversion were 25%. YMDD mutants were detected in 4 of 8 patients who showed sustained HBV DNA and serum ALT response (n=31) and in 3 of 8 patients who showed HBV DNA or serum ALT breakthrough (n=9). The response to lamivudine therapy in HBeAg-egative patients was excellent.
CONCLUSION
Lamivudine therapy resulted in a significant virological and biochemical improvements and were well tolerated. But, YMDD mutants were detected during lamivudine therapy.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Efficacy of New Anti-viral Agent in the Treatment of Chronic Hepatitis B
- The management and treatment of chronic hepatitis B in Korean children
- Lamivudine Rescue from the Accelerating Course of Chronic Hepatitis B
- Efficacy of 1-Year Lamivudine Treatment in the Patient of Chronic B Hepatitis and Liver Cirrhosis
- The Effect of Lamivudine Therapy for Chronic Liver Disease due to Hepatitis B Virus Infection
